康哲药业(00867)公布2025年业绩拥有人应占溢利约14.89亿元同比减少8.08%

智通财经03-16

智通财经APP讯，康哲药业(00867)公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。该集团以“合作开发+自主研发”模式打造“近端确定性、远端成长性”兼备的创新引擎。“合作开发”保障了短、中期管线的丰富度与竞争力，快速拓宽产品矩阵;“自主研发”深度布局前沿技术领域...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2619165464?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-16 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619165464","market":"sh","top_or_hot":-1,"title":"康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康哲药业(00867)公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。该集团以“合作开发+自主研发”模式打造“近端确定性、远端成长性”兼备的创新引擎。“合作开发”保障了短、中期管线的丰富度与竞争力，快速拓宽产品矩阵;“自主研发”深度布局前沿技术领域...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414600.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-16 22:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1414600.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康哲药业(00867)公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。该集团以“合作开发+自主研发”模式打造“近端确定性、远端成长性”兼备的创新引擎。“合作开发”保障了短、中期管线的丰富度与竞争力，快速拓宽产品矩阵;“自主研发”深度布局前沿技术领域...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414600.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1414600.html","article_id":"2619165464","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619165464","pubTimestamp":1773672729,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康哲药业 公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。已上市创新药加速放量，逐步形成推广规模效应。回望2025年，康哲药业已实现里程碑式的战略突破。集团正以卓越的发展韧性与战略张力，稳步成长为一家根植中国、竞逐全球新兴市场的创新驱动型国际化医药企业，为全球医药健康事业创造长远价值。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1593":"医美概念股","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","BK1191":"制药","00867":"康哲药业","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD"},"translate_title":"Kangzhe Pharmaceutical (00867) announced its 2025 results. Profit attributable to owners was approximately 1.489 billion yuan, a year-on-year decrease of 8.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1.5},"content_text":"智通财经APP讯，康哲药业(00867)公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。该集团以“合作开发+自主研发”模式打造“近端确定性、远端成长性”兼备的创新引擎。“合作开发”保障了短、中期管线的丰富度与竞争力，快速拓宽产品矩阵;“自主研发”深度布局前沿技术领域，构筑长期发展的基石和创新源动力。2025年以来，集团梯队化创新矩阵不断扩容提质：2款新药获批上市，分别为百卢妥(磷酸芦可替尼乳膏) - 白癜风(2026年1月中国获批上市)及德昔度司他片(2026年3月中国获批上市)。已上市创新药加速放量，逐步形成推广规模效应。六款创新药正处于中国新药上市申请(NDA)审评阶段，为后续增长储备动能，分别为注射用洛贝米柳(注射用Y-3)及年内新增创新产品斯乐韦米单抗注射液与唯康度塔单抗注射液、葡萄糖酸苯加兰他敏肠溶片(ZUNVEYL)、柯美奇拜单抗注射液(MG-K10 - 特应性皮炎(AD))及磷酸芦可替尼乳膏 - AD(2026年2月中国 NDA获受理)。拥有全球权益的自研产品GnRH受体拮抗剂(CMS-D002)、GLP-1R/GCGR双重激动剂(CMS-D005)、心肌肌球蛋白抑制剂(CMS-D003)、TYK2抑制剂(CMS-D001)、补体因子B抑制剂(CMS-D017)(2026年3月进入中国I期临床)的临床开发工作有序推进，构建起自主创新资产蓄水池。该集团深耕专科疾病治疗领域，在核心市场外，前瞻性扩展以“新零售、数字渠道、消费医疗”为核心的院外增长引擎，承接处方外流、多元支付与消费健康需求，强化渠道和品牌驱动，以院外生态打开增量空间。集团皮肤健康业务“德镁医药”在中国皮肤健康领域已处于行业领先地位，将通过介绍上市、实物分派方式，拟分拆于香港联交所主板独立上市，助力其独立价值与高成长潜力的全面释放。此外，积极深化“产业国际化”布局，构筑起“研、产、销”全生态链的高效协同体系。2025年7月15日，集团以介绍方式成功于新交所完成第二上市，并以此为支点，推进新兴市场纵深拓展，构建起多区域、可持续的增长新格局。回望2025年，康哲药业已实现里程碑式的战略突破。未来，伴随“新康哲”战略的全面推进，集团将始终以创新为源动力，持续驱动院内外协同的多元商业化生态建设，加速“产业国际化”体系优势于新兴市场兑现，并将AI数智化赋能贯穿运营与管理。集团正以卓越的发展韧性与战略张力，稳步成长为一家根植中国、竞逐全球新兴市场的创新驱动型国际化医药企业，为全球医药健康事业创造长远价值。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619165464","isCrawlerRequest":true}

康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%

精彩评论

康哲药业(00867)公布2025年业绩拥有人应占溢利约14.89亿元同比减少8.08%